Small science, giant steps: The AIBN 2022 in review
Published on: 6 December 2022
Chappell Group
Utilising Molecular Clamp technology to research and develop vaccines
The Chappell Group, led by Group Leader Professor Keith Chappell, is primarily focused on the research and development of vaccines for medically important viruses utilising Molecular Clamp technology.
The current second-generation molecular clamp platform enables the rapid generation of viral subunit vaccines, which are safe, elicit an optimal response, are rapid to produce, cost-effective and thermal stable.
The team have two major projects; one funded by the Coalition for Epidemic Preparedness Innovations (CEPI), which focuses on building a rapid response vaccine pipeline to safeguard against future pandemics, and the second comprising contract research for UQ spinout, Vicebio Pty Ltd, that seeks to develop improved vaccines for respiratory viruses.
Research Areas
- Vaccines
- Molecular clamp technology
- Monoclonal antibodies
Research Approach
Additional research undertaken within the Chappell group is focused on understanding medically and environmentally important viruses. Such projects include the discovery of monoclonal antibodies for use as diagnostics and therapeutics, research into Koala retrovirus and its impacts the health of Australia’s wild koala populations, and pre-clinical development of a vaccine for Human T- Lymphotropic virus type 1 (HTLV-1).
Research Projects
-
KORV
January 2007–December 2027 -
Preclinical Development of a vaccine for HTLV-1
January 2019–December 2026 -
ViceBio
January 2019–December 2024 -
Rapid Response Vaccine Pipeline
January 2019–December 2026
